The objective of the current study is to formulate encapsulated sildenafil citrate Immediate Release (IR) and Bosentan sustained release Minitablets (MTs) for treating pulmonary arterial hypertension. This piece of research work signifies a targeted dosage form that is designed in the form of encapsulated minitablets taking different super disintegrants and polymers which produces superior product quality. In vivo pharmacokinetic studies of prepared mini tablets are also showed promising results. Using different concentrations of polymers like HPMC K15M, ethyl cellulose and sodium CMC for Bosentan SR tablets, while for sildenafil citrate IR super disintegrants like sodium starch glycollate, magnesium aluminium silicate (Veegum-HV) and crosslinked PVP are taken for the manufacturing of MTs. All the pre compression and post compression parameters are carried out. The investigation showed that formulation S6 for sildenafil citrate IR MTs showed a desirable and optimistic profile for immediate release within 10 minutes, whereas formulation B3 for Bosentan SR MTs showed promising sustained release action for about 24 hours. In vivo pharmacokinetic parameters also show promising results towards the formulation and encapsulation. Therefore, the creation of encapsulated MTs with two active pharmaceutical ingredients could boost patient medication compliance and serve as a platform to get over the technical as well as financial limitations associated with current dosage forms as well as time-consuming and expensive expenditures.
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 15261 citations as per Google Scholar report